CROX — Crocs, Inc.

Sell-side sentiment is moderately bullish: 19 Buy vs 3 Sell ratings, a 'Buy' consensus, and a $136.78 consensus price target / $134.33 recent average, both implying double-digit upside from the $118.09 print on 2026-10-04. The drivers are the late-July 2026 Q2 beat with raised full-year guidance, the Crocs brand crossing $1B in quarterly revenue for the first time, double-digit international growth in China, India and Japan, and a $1.5B expansion of the buyback (to ~$2B authorized). The offset: a 6.4% one-week drop and renewed gross-margin/tariff worry mean the bullishness is conviction-in-earnings rather than conviction-in-the-tape.

Revenue went from low-single-digit growth to an outright decline and has just inflected back: YoY growth ran +1.6% (Q3 2024), +3.1% (Q4 2024), -0.1% (Q1 2025), +3.4% (Q2 2025), then -6.2% (Q3 2025), -3.2% (Q4 2025), -1.7% (Q1 2026) before returning to +2.6% in Q2 2026 on record revenue of $1,179.5M. That three-quarter negative stretch looks like the HEYDUDE-driven air pocket, not structural decline, and Q2 2026 is the first hard evidence of a bottom. Margins are the real problem: operating margin compressed on a clean like-for-like basis every year - Q2 29.3% (2024) to 27.0% (2025) to 24.2% (2026); Q4 20.2% (2024) to 15.3% (2025); Q1 24.1% to 23.8% to 21.8%. Gross margin fell to 59.4% in Q2 2026 from 61.7% a year earlier (~230bps), consistent with tariffs/promo. Earnings quality is clean - Q2 2025's -$492M net loss (EPS -$8.82) was a non-cash HEYDUDE impairment, and the most recent four quarters (Q3 2025 through Q2 2026) carry no such charge, with diluted EPS of $2.70, $2.03, $2.71 and a record $4.12. Note that Q2 2026 EPS of $4.12 beat Q2 2024's $3.77 despite a 510bp margin decline - net income was actually lower ($204.9M vs $228.9M), so most EPS growth is share-count reduction from buybacks (equity has fallen to $1.38B from $1.97B in Q1 2025). Verdict: revenue inflecting up, margins still trending down but decelerating, EPS growth currently buyback-driven.

Cheap-to-fair, with the cheapness concentrated in forward numbers. As of 2026-10-04: trailing P/E 10.13x (EPS TTM $11.94) against a 5-year average trailing P/E of 9.35x - i.e. modestly above its own history on trailing earnings; forward P/E of 8.46x on the $13.95 next-FY estimate; P/S 1.40x against a 5-year average of 1.90x (a ~26% discount); EV/EBITDA 8.39x; P/B 4.24x. The TTM PEG of -0.025 is meaningless - it is computed off GAAP growth distorted by the Q2 2025 impairment. The real story: consensus next-FY revenue of $4.101B is essentially flat versus the ~$4.05-4.13B current run-rate, so the modeled step-up to $13.95 EPS is coming from margin stabilization plus buyback-driven share reduction, not top-line growth. A high-margin (57.5% gross), high-FCF business at 8.5x forward earnings is genuinely inexpensive - the discount is the market pricing permanent low-single-digit growth, HEYDUDE uncertainty and tariff risk.

The price is discounting almost nothing: 8.5x forward EPS for a business generating ~$705M of TTM free cash flow against a $5.66B market cap (12.4% FCF yield) implies the market expects zero margin recovery and flat-to-declining revenue. The asymmetry is the buyback: ~$2B of authorization equals roughly 35% of the entire market cap, so even flat earnings could produce high-single-to-double-digit EPS growth for several years - which is why consensus sits at $136.78 while the stock trades at $118.09. Where the market could be wrong in either direction: (1) if gross margin holds near 59% and Q2's +2.6% revenue growth proves to be the start of a trend, 9.5-10x forward EPS is easily justified and the stock re-rates toward $135-140; (2) if operating margin keeps sliding 200-300bps per year as it has for three years, the 'flat earnings + buyback' math stalls and 8x is fair, not cheap. Watch the Q3 print on 2026-10-29 for the first real read on whether the revenue inflection is durable - one quarter is not a trend.

Mixed-to-constructive long frame, deteriorating short frame. As of 2026-10-04, RSI(14) stood at 45.22 - dead neutral, neither oversold nor overbought, so there is no capitulation signal to buy. Price of $118.09 was -0.35% versus the 20-day SMA (essentially at it), -5.11% versus the 50-day, and +10.91% versus the 200-day, which puts the long-term uptrend intact but the intermediate trend broken. The one-week return of -6.38% against a one-month +1.99%, three-month -5.74% and six-month +41.15% describes a strong six-month advance that is currently unwinding - the 52-week range is $73.21-$141.28 and the stock has given back from the upper end. Implication: this is a pullback inside an uptrend, not a washed-out bottom. Better entries are either a reclaim of the 50-day (roughly the $124 area) confirming the pullback is over, or a flush toward the 200-day (roughly $106-107) where the risk/reward improves markedly. Buying at RSI 45 with the 50-day overhead is neither.

• Consumer discretionary bifurcation: upper-middle-income demand for casual footwear remains resilient, but value-conscious shoppers are inflation-sensitive - Crocs' roughly $50-70 core product straddles both cohorts, making unit demand macro-levered.
• Tariffs and imported-goods costs: footwear is import-heavy and tariff shifts are the single largest swing factor on gross margin, already visible in the 230bp YoY gross margin decline to 59.4% in Q2 2026.
• Rates and leverage cost: $1.31B of long-term debt against only $170M of cash (net debt ~$1.14B, debt/equity 1.22), with a beta of 1.51 - the stock is rate-sensitive and a large buyback could be debt-funded.
• FX translation: meaningful and fast-growing international revenue (double-digit growth in China, India and Japan) means a strong dollar is a mechanical revenue and margin headwind.
• Wholesale channel health and inventory discipline: retail partners' inventory caution amplifies or dampens the DTC/wholesale mix shift; high-margin DTC expansion has been the main margin offset to HEYDUDE weakness.

• Q3 2026 earnings on 2026-10-29 (estimated) - the first read on whether Q2's +2.6% revenue inflection is durable into the holiday build, and the first update on raised full-year guidance.
• Execution of the expanded share repurchase program - roughly $2B authorized versus a $5.66B market cap, the single largest mechanical driver of EPS growth from here.
• Evidence of a HEYDUDE turnaround or, conversely, another write-down: HEYDUDE caused the Q2 2025 ~$492M impairment and remains the main reason the multiple stays compressed.
• Gross margin stabilization against tariffs - holding near 59% would remove the biggest bear argument and support a re-rating toward 9.5-10x forward earnings.
• Continued international expansion (China, India, Japan) and new brand/marketing initiatives such as the 'Niles' mascot and AI-assisted digital conversion rolled out in September 2026.

• Persistent margin erosion: operating margin has fallen every comparable quarter for three years (Q2 24.2% in 2026 vs 27.0% in 2025 vs 29.3% in 2024), and if that pace continues the buyback math stops working.
• HEYDUDE brand risk: the turnaround is unproven, the segment already produced a ~$492M impairment in Q2 2025, and further write-downs or continued decline would keep the valuation multiple depressed.
• Balance-sheet flexibility: $1.31B of long-term debt against $170M of cash, with stockholders' equity cut to $1.38B (from $1.97B in Q1 2025) by buybacks - a $2B authorization funded aggressively could strain the balance sheet or crowd out other uses of cash.
• Single-silhouette concentration and fashion risk: the clogs/sandals franchise carries the branded economics, making the company unusually exposed to a change in consumer taste or a promotional price war.
• Consumer cyclicality and macro sensitivity: beta of 1.51 plus value-segment inflation pressure means a discretionary spending slowdown would hit both revenue and the multiple simultaneously.

Crocs is a high-margin, high-cash-conversion business priced like a value trap: ~$705M of trailing free cash flow against a $5.66B market cap (12.4% yield), 8.5x forward earnings, 1.4x sales against a 1.9x five-year average, and a ~$2B buyback authorization worth roughly 35% of the market cap. The core Crocs brand is demonstrably fine - record $1.18B revenue in Q2 2026, first $1B+ Crocs-brand quarter, raised guidance - and the awful-looking GAAP ROE (-6.3%) and ROIC (-27.7%) printed in the data are artifacts of a non-cash Q2 2025 HEYDUDE impairment, not operating deterioration. The genuine problem is that operating margin has compressed roughly 200-300bps per year for three straight years, so today's EPS growth is coming from share count, not pricing power or leverage. That makes this a 'buy the cash flow, not the growth story' setup: reasonably attractive on a 12-month view with a raised guide and a massive buyback, but not an obvious slam dunk, and the tape (below the 50-day, RSI 45, -6.4% on the week) argues against chasing it right here. This is analysis, not personalized financial advice.

Primary method: 9.5x forward P/E applied to the $13.95 next-FY consensus EPS = $132.53, where 9.5x is a modest premium to the 5-year average trailing P/E of 9.35x, justified by the raised FY2026 guide, the ~$2B buyback and the return to positive revenue growth in Q2 2026. Cross-checks: 8.2x EV/EBITDA on roughly $900M of forward EBITDA less ~$1.14B of net debt and 47.95M shares gives about $130/share, and an 11% required FCF yield on ~$710M of trailing free cash flow gives about $135/share - the three methods triangulate to ~$132 versus the $118.09 price on 2026-10-04.